tirzepatide court case update Lilly Wins Battle Against Compounders as Judge Backs FDA: No Longer in Shortage US judge denies injunction, restricting

Patients with high genetic risk scores receive closer monitoring protocols or may be guided toward alternative compounds or microdose protocols that reduce pancreatic stimulus while preserving efficacy

You may have seen microdosing of GLP-1s advertised with promises of fewer side effects and better longevity, though there's no clear scientific definition of microdosing, and we dont yet have data to know if these medications prolong life (except for people with known cardiovascular disease)

Prescribing to patients who dont meet clinical criteriaas sometimes happens with celebrities and social media influencerscontributes to misuse, stigma and misunderstanding of what these medications are for

Concerns around potential side effects are a known reason people choose not to take GLP-1 drugs